The trials’ questionable methodology generated “uncertainties” so significant that they undermine claims of efficacy.The ages of the women who participated in the trials were not representative of the younger adolescents who constitute HPV vaccination’s primary target groups.The studies used highly restrictive criteria to exclude many potential participants, limiting the trials’ “relevance and validity for real world settings.” (During Science Day presentations for the Jennifer Robi vs. Merck and Kaiser Permanente Gardasil lawsuit in January 2019, Robert F. Kennedy, Jr. made the same point, describing the “elite club of superheroes” who constituted the study group and noting that Merck purged anyone with the slightest vulnerabilities to the vaccine or its ingredients despite the fact that the vaccine would ultimately be marketed to girls .)The trials used “composite and distant surrogate outcomes” that essentially made it “impossible to determine effects on clinically significant outcomes.” The authors explain that the surrogate outcomes used (forms of cervical dysplasia called CIN1 and CIN2) often regress on their own “and are of limited clinical concern.” They also note that different forms of cervical dysplasia each have “their own different natural histories, prevalence and incidence and strength of association with cancer.” Lumping together vastly different forms of dysplasia into the trials’ composite surrogate endpoints, therefore, was “problematic.”https://www.ageofautism.com/2020/01/negative-efficacy-uk-cervical-cancer-rate-rising-in-teens-vaccinated-for-hpv.html
